Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...

On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

INDIANAPOLIS: Drugmaker Eli Lilly and Co.'s second-quarter earnings fell 11 percent as it hiked marketing and research expenses to gear for a wave of patent expirations that will slash sales for ...

Core PCE Inflation Matches Estimates for AprilFri, 31 May 2024 12:48:04 GMT Euro Area Inflation Rises to 2.6%, Core CPI Jumps to 2.9%Fri, 31 May 2024 12:23:10 GMT German Retail Sales Slide by 1.2% ...

Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and diabetes medications Mounjaro and Zepbound, the pharmaceutical firm said ...

Eli Lilly and Company announced that Anat Ashkenazi has decided to step down as chief financial officer. 1 She will continue to serve in the role through July 2024, at which point she will pursue a ...

Market Chatter: Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second ...

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar ...

, opens new tab named Anat Ashkenazi as its chief financial officer on Wednesday, turning to a top executive from drugmaker Eli Lilly (LLY.N) , opens new tab to help steer the Google parent in the ...

Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...

On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares. The ...